Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer

Clinical benefit of ALK tyrosine kinase inhibitors (ALK‐TKIs) in ALK‐rearranged lung cancer has been limited by the inevitable development of acquired resistance, and bypass‐molecular resistance mechanisms remain poorly understood. We investigated a novel therapeutic target through screening FDA‐app...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EMBO Mol Med
Main Authors: Yun, Mi Ran, Choi, Hun Mi, Lee, You Won, Joo, Hyeong Seok, Park, Chae Won, Choi, Jae Woo, Kim, Dong Hwi, Kang, Han Na, Pyo, Kyoung‐Ho, Shin, Eun Joo, Shim, Hyo Sup, Soo, Ross A, Yang, James Chih‐Hsin, Lee, Sung Sook, Chang, Hyun, Kim, Min Hwan, Hong, Min Hee, Kim, Hye Ryun, Cho, Byoung Chul
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6895608/
https://ncbi.nlm.nih.gov/pubmed/31633304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201910581
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados